| 1 |
33805706 | SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin Bioavailability. | 2021 Mar 13 |
1 |
| 2 |
26932749 | Genetic determinants of lipid-lowering response to atorvastatin therapy in an Indian population. | 2016 Jun |
1 |
| 3 |
27296832 | ABCB1 polymorphism is associated with atorvastatin-induced liver injury in Japanese population. | 2016 Jun 13 |
1 |
| 4 |
26273214 | CYP3A5 genotyping for assessing the efficacy of treatment with simvastatin and atorvastatin. | 2015 May |
4 |
| 5 |
26293521 | Interactions between CYP3A5*3 and POR*28 polymorphisms and lipid lowering response with atorvastatin. | 2015 Sep |
2 |
| 6 |
22120734 | Identification of pharmacogenetic predictors of lipid-lowering response to atorvastatin in Chilean subjects with hypercholesterolemia. | 2012 Feb 18 |
1 |
| 7 |
22882727 | CYP7A1 polymorphism influences the LDL cholesterol-lowering response to atorvastatin. | 2012 Dec |
1 |
| 8 |
21950641 | Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin. | 2011 Oct |
2 |
| 9 |
21105332 | [Effect of polymorphisms of cytochrome P450 and apolipoprotein E genes on therapeutic efficacy of statins]. | 2010 |
1 |
| 10 |
18720283 | Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin. | 2008 Sep |
2 |
| 11 |
18727922 | CYP3A53A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia. | 2008 Dec |
1 |
| 12 |
15900215 | Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage. | 2005 Jun |
1 |
| 13 |
15284534 | Lipid-lowering response to statins is affected by CYP3A5 polymorphism. | 2004 Aug |
2 |